EMA recommends approvals for both oral and high-dose pen of Wegovy
Both an oral formulation and a high-dose injectable version of Novo Nordisk’s Wegovy (semaglutide) are edging closer to the European…
26 May 2026
Eli Lilly to buy trio of vaccine developers in $3.8bn outlay
Eli Lilly has agreed to buy three vaccine-specialist biotechs in a bolstering of its infectious disease portfolio, continuing the drugmaker’s streak of dealmaking in 2026. Lilly has outlaid up to…
26 May 2026
University of Edinburgh develops cell therapy for liver disease
Scientists at the University of Edinburgh have developed a new cell therapy aiming to provide a potential alternative to liver transplants for patients with advanced liver disease. The therapy uses…
26 May 2026
Pierre Fabre’s Braftovi gains CHMP positive opinion for mCRC
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of Pierre Fabre Laboratories’ Braftovi (encorafenib) for the treatment of…
25 May 2026
AstraZeneca, Daiichi Sankyo’s Datroway receives FDA approval for TNBC
AstraZeneca and Daiichi Sankyo have secured approval from the US Food and Drug Administration (FDA) for Datroway (datopotamab deruxtecan) to treat metastatic triple-negative breast cancer (TNBC). The approval allows Datroway…
22 May 2026
CVC consortium tables $12.4bn bid to delist Italian drugmaker Recordati
One of Italy’s only publicly traded large pharma companies could soon be taken into private ownership, after private equity firm CVC Capital Partners and Belgian investment group Groupe Bruxelles Lambert…
22 May 2026
European STI cases reach record high amid testing and prevention gaps
New data debuted by the Europe’s infectious disease agency has revealed that cases of certain bacterial sexually transmitted infections (STIs) reached a ten-year high in 2024 as healthcare systems grapple…